US4377567A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Lipid membrane drug delivery
Assignee: Procter and Gamble Co
•
Filing: 1979-09-13
•
Granted: 1983-03-22
•
Expires: 1999-09-13
Abstract
Abstract Lipid Membrane Structures comprising Digalactosyl Diglyceride target the liver of humans and lower animals and are used to carry drugs to that organ, preferentially. Digalactosyl Diglyceride LMS containing insulin provide an effective means for treating diabetes mellitus. Digalactosyl Diglyceride LMS containing interferon are used to treat viral hepatitis.
Inventors
- 👤 Walter B. Geho
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:20
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K38/22; A61K38/28; A61K51/00; A61K51/12; A61K51/1217; A61K51/1227; A61K51/1234; A61K9/00; A61K9/10; A61K9/127; A61K9/1271; A61K9/1272; A61K2123/00; Y; Y10; Y10S; Y10S424/00; Y10S424/06
Claims Analysis
Total Claims: 41
Claim 1
Independent Claim
93 words
A composition of matter for internal administration in the therapeutic treatment of a human or animal comprising: (A) a first component which is a drug or diagnostic agent, said first component being encapsulated in or associated with; (B) a second component which comprises lipid membrane structures in the form of vesicles or liposomes, having an average particle diameter of between about 250 Angstroms and about 3000 Angstroms, which comprise a mixture of a major portion of a polar lipid and a minor portion of a digalactosyl derivative having at least one fatty substituent.
Claim 2
Dependent Claim
93 words
A composition of matter for internal administration in the therapeutic treatment of a human or animal comprising: (A) a first component which is a drug or diagnostic agent, said first component being encapsulated in or associated with; (B) a second component which comprises lipid membrane structures in the form of vesicles or liposomes, having an average particle diameter of between about 250 Angstroms and about 3000 Angstroms, which comprise a mixture of a major portion of a polar lipid and a minor portion of a digalactosyl derivative having at least one fatty substituent.
Claim 3
Dependent Claim
32 words
A composition according to claim 1 comprising from about 90% to about 99.5% by weight of the polar lipid and from about 0.5% to about 10% by weight of the digalactosyl derivative.
Claim 4
Dependent Claim
33 words
A composition according to claim 2 which comprises from about 95% to about 99% by weight of the polar lipid and from about 1% to about 5% by weight of the digalactosyl derivative.
Claim 5
Dependent Claim
28 words
A composition according to claim 1 wherein the polar lipid comprises a dialkanoyl lecithin wherein the alkanoyl groups each contain from about 12 to about 20 carbon atoms.
Claim 6
Dependent Claim
20 words
A composition according to claim 4 wherein the alkanoyl groups are selected from the group consisting of palmitoyl and stearoyl.
Claim 7
Dependent Claim
13 words
A composition according to claim 5 wherein the polar lipid is distearoyl lecithin.
Claim 8
Dependent Claim
39 words
A composition according to claim 1 wherein the digalactosyl derivative is a fatty glyceride digalactosyl derivative characterized by at least one fatty substituent having a chain length in the range from about C 12 to about C 20 .
Claim 9
Dependent Claim
13 words
A composition according to claim 7 wherein the digalactosyl derivative is Digalactosyl Diglyceride.
Claim 10
Dependent Claim
38 words
A composition according to claim 1 wherein the Lipid Membrane Structures comprise a mixture of from about 94% to about 97% by weight of distearoyl lecithin and from about 3% to about 6% by weight of Digalactosyl Diglyceride.
Claim 11
Dependent Claim
25 words
A composition according to claim 9 wherein said vesicles or liposomes are in a size range of from about 750 Angstroms to about 3000 Angstroms.
Claim 12
Dependent Claim
22 words
A composition according to claim 1 or 9 in a liquid electrolyte-containing carrier suitable for injection into a human or lower animal.
Claim 13
Dependent Claim
24 words
A composition according to claim 1 or 9 which comprises, as an additional ingredient in the Lipid Membrane Structures, a stabilizing amount of cholesterol.
Claim 14
Dependent Claim
17 words
A composition according to claims 1, 8, 9 or 10 wherein said first component comprises a radionuclide.
Claim 15
Dependent Claim
24 words
A composition according to claim 13 wherein said radionuclide is selected from the group consisting of technetium-99m, thallium-201, indium-113m, indium-111, fluorine-18, strontium-85 and iodine-125.
Claim 16
Dependent Claim
19 words
A composition according to claim 1, 8, 9 or 10 wherein said first component is a heavy metal chelator.
Claim 17
Dependent Claim
23 words
A composition according to claim 15 wherein said heavy metal chelator is selected from the group consisting of the ethylenediaminetetraacetates and the diethylenetriaminepentaacetates.
Claim 18
Dependent Claim
16 words
A composition according to claim 1 wherein said first component comprises insulin, or an insulin derivative.
Claim 19
Dependent Claim
33 words
An insulin composition according to claim 17 comprising from about 90% to about 99.9% by weight of the polar lipid and from about 0.1% to about 10% by weight of the digalactosyl derivative.
Claim 20
Dependent Claim
34 words
An insulin composition according to claim 18 which comprises from about 95% to about 99% by weight of the polar lipid and from about 1% to about 5% by weight of the digalactosyl derivative.
Claim 21
Dependent Claim
29 words
An insulin composition according to claim 17 wherein the polar lipid comprises a dialkanoyl lecithin wherein the alkanoyl groups each contain from about 12 to about 20 carbon atoms.
Claim 22
Dependent Claim
21 words
An insulin composition according to claim 20 wherein the alkanoyl groups are selected from the groups consisting of palmitoyl and stearoyl.
Claim 23
Dependent Claim
14 words
An insulin composition according to claim 21 wherein the polar lipid is distearoyl lecithin.
Claim 24
Dependent Claim
40 words
An insulin composition according to claim 17 wherein the digalactosyl derivative is a fatty glyceride digalactosyl derivative characterized by at least one fatty substituent having a chain length in the range from about C 12 to about C 20 .
Claim 25
Dependent Claim
14 words
An insulin composition according to claim 23 wherein the digalactosyl derivative is Digalactosyl Diglyceride.
Claim 26
Dependent Claim
36 words
An insulin composition according to claim 17 wherein the Lipid Membrane Structures comprise a mixture of from about 94% by weight of distearoyl lecithin and from about 3% to about 6% by weight of Digalactosyl Diglyceride.
Claim 27
Dependent Claim
26 words
An insulin composition according to claim 25 wherein said vesicles or liposomes are in a size range of from about 750 Angstroms to about 3000 Angstroms.
Claim 28
Dependent Claim
25 words
An insulin composition according to claim 17 25 or 26 dispersed in a liquid electrolyte-containing carrier suitable for injection into a human or lower animal.
Claim 29
Dependent Claim
20 words
An insulin composition according to claim 17 or 26 which comprises, as an additional ingredient, a stabilizing amount of cholesterol.
Claim 30
Dependent Claim
12 words
A composition according to claim 1 wherein said first component comprises interferon.
Claim 31
Dependent Claim
33 words
An interferon composition according to claim 29 comprising from about 90% to about 99.9% by weight of the polar lipid and from about 0.1% to about 10% by weight of the digalactosyl derivative.
Claim 32
Dependent Claim
36 words
An interferon composition according to claim 30 which comprises from about 95% to about to about 99% by weight of the polar lipid and from about 1% to about 5% by weight of the digalactosyl derivative.
Claim 33
Dependent Claim
29 words
An interferon composition according to claim 29 wherein the polar lipid comprises a dialkanoyl lecithin wherein the alkanoyl groups each contain from about 12 to about 20 carbon atoms.
Claim 34
Dependent Claim
21 words
An interferon composition according to claim 32 wherein the alkanoyl groups are selected from the group consisting of palmitoyl and stearoyl.
Claim 35
Dependent Claim
14 words
An interferon composition according to claim 33 wherein the polar lipid is distearoyl lecithin.
Claim 36
Dependent Claim
40 words
An interferon composition according to claim 29 wherein the digalactosyl derivative is a fatty glyceride digalactosyl derivative characterized by at least one fatty substituent having a chain length in the range from about C 12 to about C 20 .
Claim 37
Dependent Claim
14 words
An interferon composition according to claim 35 wherein the digalactosyl derivative is Digalactosyl Diglyceride.
Claim 38
Dependent Claim
39 words
An interferon composition according to claim 29 wherein the Lipid Membrane Structures comprise a mixture of from about 94% to about 97% by weight of distearoyl lecithin and from about 3% to about 6% by weight of Digalactosyl Diglyceride.
Claim 39
Dependent Claim
26 words
An interferon composition according to claim 37 wherein said vesicles or liposomes are in a size range of from about 750 Angstroms to about 3000 Angstroms.
Claim 40
Dependent Claim
25 words
An interferon composition according to claim 29, 37 or 38 dispersed in a liquid electrolyte-containing carrier suitable for injection into a human or lower animal.
Claim 41
Dependent Claim
20 words
An interferon composition according to claim 29 or 37 which comprises, as an additional ingredient, a stabilizing amount of cholesterol.
References Cited (Backward Citations)
US3937668A
Cited
ZA731850B
Cited
BE830629A
Cited
DE2532317A1
Cited
US3957971A
Cited
DE2650502C3
Cited
DE2656333A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-03-21 | 1986-09-20 | 1987-03-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-03-21 | 1990-09-20 | 1991-03-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-03-21 | 1994-09-20 | 1995-03-22 | $7700.00 | Window Closed / Lapsed |